- You are here:
- Home »
- Blog »
- colon cancer »
- Pros Cons NRG-GI008 clinical trial
Pros Cons NRG-GI008 clinical trial
What are the pros and cons of the NRG-GI008 clinical trial? My name is Bernie Davis. I was diagnosed with colon cancer in 2025. I underwent surgery to remove the tumor in my colon, but I’m not sure about undergoing adjuvant chemotherapy. I received a report from the tumor board at the hospital where I had my surgery.
I was told that I should consider the NRGI008 clinical trial for colon cancer patients like me.
I’ve asked PeopleBeatingCancer.org to research the pros and cons of this trial.
What are the pros and cons of a stage 3 colon cancer patient entering the NRG-GI008 clinical trial?
Short answer up front: NRG-GI008 (aka CIRCULATE-North America) is a randomized phase II/III trial that uses a tumor-informed ctDNA (Signatera) result after surgery to guide whether patients receive adjuvant chemotherapy (and if so, what intensity). Entering the trial can spare some patients unnecessary chemo and intensify therapy for those at highest risk, but it also means randomization, extra testing/visits, and the chance of receiving either less treatment than you’d otherwise get (if ctDNA-guided de-escalation proves inferior) or more toxic treatment (if randomized to intensified therapy). NRG Oncology+1
Below is a patient-friendly list of the main pros and cons, with the most important supporting facts cited.
Pros
-
Personalized treatment decision: the trial uses a tumor-informed ctDNA MRD assay (Signatera) to determine risk and then adapt therapy (less chemo or more chemo depending on ctDNA). That can avoid one-size-fits-all approaches. NRG Oncology+1
-
Potential to avoid adjuvant chemotherapy and its toxicities if you are ctDNA-negative and randomized to less-intensive strategy — fewer immediate side effects (neuropathy, cytopenias, GI side effects) and less long-term toxicity (e.g., persistent neuropathy from oxaliplatin). NRG Oncology+1
-
Potential to improve outcomes if you are ctDNA-positive: the trial tests intensifying adjuvant therapy (mFOLFIRINOX-style approach) for ctDNA+ patients who are at high risk of recurrence — this could reduce relapse risk for those with microscopic residual disease. Tower Health+1
-
Structured, closer surveillance and standardized follow-up: being on trial typically means more frequent ctDNA checks, scheduled imaging/visits, and quicker escalation of treatment if recurrence signals appear. This can catch relapse earlier. NRG Oncology
-
Contributing to research: participation helps build high-quality evidence that may spare future patients unnecessary chemo or identify who benefits from intensification. NRG Oncology
Cons / Risks
-
Randomization and uncertainty: you may be randomized to a strategy you would not choose outside the trial (e.g., less chemo if ctDNA-negative, or intensified chemo if ctDNA-positive). The long-term superiority of either approach is exactly what the trial is testing. NRG Oncology
-
False negatives / false reassurance: ctDNA assays are highly sensitive but not perfect. A ctDNA-negative result could miss tiny residual disease (false negative), so de-escalation could theoretically leave untreated microscopic cancer. That’s why the question must be tested in a randomized trial. Natera+1
-
Increased toxicity with intensified regimens: if randomized to intensification (mFOLFIRINOX or similar), you face substantially higher acute and sometimes long-term toxicities (neutropenia, severe diarrhea, fatigue, neuropathy, risk of treatment interruptions). These regimens are more aggressive than standard single-agent oxaliplatin/5-FU approaches. Tower Health+1
-
Extra procedures, visits, and logistics: trial participation requires serial blood draws for central Signatera testing, scheduled clinic visits, and possibly travel to a participating center; there can be more paperwork and time commitment. crcwm.org+1
-
Eligibility constraints / insurance / costs: you must meet trial criteria (e.g., R0 resection, within the allowed postoperative window, ECOG 0–1, be a candidate for the trial chemo agents). Some local insurers or providers may require pre-authorization for tests or treatments; logistics vary by site. NRG Oncology+1
Practical considerations you should discuss with your oncologist
-
Your baseline fitness and comorbidities: can you safely tolerate an intensified regimen (if randomized to it)? (cardiac function, neuropathy risk, performance status) NRG Oncology+1
-
Your preferences about risk vs toxicity: would you rather take a small added relapse risk to avoid chemo side effects, or accept higher toxicity to try to lower relapse risk? Trials trade off exactly these things.
-
Travel/time burden: is there a conveniently located trial site? Will additional visits or blood draws be a problem? duke-research.dukehealth.org
-
How ctDNA results would change your peace of mind: some patients find serial MRD monitoring reassuring; others find positive ctDNA results anxiety-provoking.
-
Insurance and test access: the trial uses central Signatera testing; discuss whether there are any out-of-pocket costs or coverage issues at your center. Natera+1
Key facts / eligibility (short)
-
Phase II/III trial for resected high-risk stage II and stage III colon cancer; requires R0 resection and candidate for the agents used (5-FU, oxaliplatin, irinotecan), usually within ~60 days of surgery and ECOG 0–1. Central ctDNA (Signatera) testing is required. NRG Oncology+1
I’m going to study this more but at first glance, the risks outweigh the benefits as far as I’m concerned. I will keep you all posted.
If you are a colon cancer survivor and you know something about this trial, the ctDNA testing, adjuvant therapy, etc. scroll down the page and let me know.
Thanks,
- Bernie Davis
- Colon Cancer Survivor
David Emerson
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
pros and cons NRG-GI008 clinical trial pros and cons NRG-GI008 clinical trial pros and cons NRG-GI008 clinical trial